PTCT · Ptc Therapeutics, Inc. · Earnings Call Transcripts & Audio
$64.78
-0.18 (-0.28%)
At close · Sep 30
View the 10-K filed Feb 19, 2026
Return incl. dividend (before tax)
Customer concentration
— top 4 customers 10% of revenue
4 customers — 10% of revenue (2025)
“During 2025, four of our distributors each accounted for over 10% of our net product sales.”
Market Cap
$5.23B
Shares
83.46M
Volume · Sep 30
1.04M
Avg daily vol (3M)
1.31M
Ptc Therapeutics, Inc. Earnings Call Transcripts
Quarterly earnings calls for Ptc Therapeutics, Inc. (PTCT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲56.5%
$217.13M
−$109.31M
'22 Q3
22-10-27
▲1.3%
$167.41M
−$170.89M
'22 Q4
23-01-09
▲48.2%
$220.38M
−$138.96M
'23 Q1
23-04-27
▲29.2%
$213.81M
−$198.88M
'23 Q2
23-08-03
▼9.5%
$196.58M
−$132.97M
'23 Q3
23-10-26
▲83.4%
$307.06M
−$155.79M
'23 Q4
24-02-29
▼4.7%
$210.12M
−$91.58M
'24 Q1
24-04-25
▼12.7%
$186.70M
−$99.18M
'24 Q2
24-08-08
▲0.1%
$196.79M
−$106.65M
'24 Q3
24-12-02
▼30.6%
$213.17M
−$65.89M
'24 Q4
25-02-27
▲459.7%
$1.18B
$866.56M
'25 Q1
25-05-06
▼4.2%
$178.88M
−$64.85M
'25 Q2
25-08-07
▲7.2%
$211.01M
$15.90M
'25 Q3
25-12-02
▼22.7%
$164.68M
−$134.97M
'25 Q4
26-02-19
▼76.8%
$272.55M
−$2.81M
'26 Q1
26-04-28
LATEST
▲101.5%
$360.52M
$83.50M
'26 Q2
26-07-30
Earnings call
FY26 · Q2
2026-07-30
Ptc Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
Confident tone
Suffiance/Duchenne launch momentum
PTC-303 splicing/HD program
Switching dynamics and real-world data
Revenue
$360.52M
▲ 101.5% YoY Diluted EPS
$0.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Ptc Therapeutics, Inc. (PTCT) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-28
Ptc Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
Confident tone
Seysara (suffiance) global launch momentum
International expansion and Japan launch
2026 financial guidance raise
Revenue
$272.55M
▼ 76.8% YoY Diluted EPS
$-0.03
▼ 100.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
Ptc Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
Confident tone
Sephience (sepiapterin) launch
Vatiquinone regulatory path
Huntington's disease program (votoplam)
Revenue
$164.68M*
▼ 22.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-12-02
Ptc Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript
Confident tone
Sephience global launch
International expansion
DMD franchise and revenue
Revenue
$211.01M
▲ 7.2% YoY Diluted EPS
$0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Ptc Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript
Confident tone
Sephience (PKU) launch
Duchenne muscular dystrophy (DMD) franchise
Vatiquinone Friedreich's ataxia NDA review
Revenue
$178.88M
▼ 4.2% YoY Diluted EPS
$-0.83
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Ptc Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript
Confident tone
SUFIANCE launch and regulatory progress
Revenue performance and guidance
DMD franchise (Translarna and Emflaza)
Revenue
$1.18B
▲ 459.7% YoY Diluted EPS
$10.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Ptc Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript
Confident tone
Commercial performance and revenue
Sepiapterin global launch (PKU)
PTC518 Huntington's disease program
Revenue
$213.17M*
▼ 30.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Ptc Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript
Positive tone
Sepiapterin for PKU
Utreloxastat (CardinALS) for ALS
Vatiquinone for Friedreich ataxia
Revenue
$196.79M
▲ 0.1% YoY Diluted EPS
$-1.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ptc Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript
Confident tone
Sepiapterin PKU launch preparation
Commercial revenue and guidance
Utreloxastat ALS
Revenue
$186.70M
▼ 12.7% YoY Diluted EPS
$-1.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Ptc Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript
Confident tone
DMD franchise (Translarna/Emflaza) revenue
Sepiapterin for PKU global launch
Utreloxastat / CardinALS in ALS
Revenue
$210.12M
▼ 4.7% YoY Diluted EPS
$-1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Ptc Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
Confident tone
Sepiapterin for PKU regulatory progress
Utreloxastat CARDINAL trial in ALS
Vatiquinone for Friedreich ataxia NDA path
Revenue
$307.06M*
▲ 83.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Ptc Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript
Revenue
$196.58M
▼ 9.5% YoY Diluted EPS
$-1.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Ptc Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript
Revenue
$213.81M
▲ 29.2% YoY Diluted EPS
$-2.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Ptc Therapeutics, Inc. (PTCT) Q1 2023 Earnings Call Transcript
Revenue
$220.38M
▲ 48.2% YoY Diluted EPS
$-1.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Ptc Therapeutics, Inc. (PTCT) Q4 2022 Earnings Call Transcript
Revenue
$167.41M*
▲ 1.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Ptc Therapeutics, Inc. (PTCT) Q3 2022 Earnings Call Transcript
Revenue
$217.13M
▲ 56.5% YoY Diluted EPS
$-1.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Ptc Therapeutics, Inc. (PTCT) Q2 2022 Earnings Call Transcript
Revenue
$165.53M
▲ 41.9% YoY Diluted EPS
$-2.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Ptc Therapeutics, Inc. (PTCT) Q1 2022 Earnings Call Transcript
Revenue
$148.74M
▲ 26.1% YoY Diluted EPS
$-1.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Ptc Therapeutics, Inc. (PTCT) Q4 2021 Earnings Call Transcript
Revenue
$165.23M*
▲ 39% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Ptc Therapeutics, Inc. (PTCT) Q3 2021 Earnings Call Transcript
Revenue
$138.74M
▲ 17.2% YoY Diluted EPS
$-1.89
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Ptc Therapeutics, Inc. (PTCT) Q2 2021 Earnings Call Transcript
Revenue
$116.68M
▲ 55.1% YoY Diluted EPS
$-1.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Ptc Therapeutics, Inc. (PTCT) Q1 2021 Earnings Call Transcript
Revenue
$117.94M
▲ 72.8% YoY Diluted EPS
$-1.83
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Ptc Therapeutics, Inc. (PTCT) Q4 2020 Earnings Call Transcript
Revenue
$118.86M*
▲ 23.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Ptc Therapeutics, Inc. (PTCT) Q3 2020 Earnings Call Transcript
Revenue
$118.40M
▲ 65.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Ptc Therapeutics, Inc. (PTCT) Q2 2020 Earnings Call Transcript
Revenue
$75.24M
▼ 12% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Ptc Therapeutics, Inc. (PTCT) Q1 2020 Earnings Call Transcript
Revenue
$68.26M
▲ 27.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Ptc Therapeutics, Inc. (PTCT) Q4 2019 Earnings Call
Revenue
$96.46M*
▲ 12.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
14 filings
11 filers
Visit website
Investor relations